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Abstract 
Rationale: The management of renal parenchymal tumors has known many changes over time, a trend that continues 
today, as a result of technological advances, clinical research and improved diagnostic and therapeutic tools. 
Unfortunately, conventional cancer treatments - chemotherapy and radiotherapy have proven ineffective and modern 
approaches such as immunotherapy, angiogenesis inhibitors, though they enjoyed an initial enthusiasm, subsequent studies have 
shown limited and controversial effects. Thus, surgery remains the gold standard therapy for this type of cancer. 
The options for the treatment of RCC are numerous, with options that have advantages and disadvantages, with 
oncological results, in most cases, positive at five years and with different impact on cancer specific survival. 
It is difficult to compare the results, as these are different techniques with various instruments and intraoperative steps, 
with more questionable inclusion criteria, selection biases and prosecution, with a tendency for preferential enrollment, different 
reasons to why randomized prospective studies have not been performed until today. 
Objective: This article is a review of the diagnosis and methods of treatment of small renal masses 2011. 
Conclusion: At the beginning of the new millennium, kidney cancer, with all the arsenal of techniques and methods of 
ablative surgery, remains a potentially fatal disease for a high percentage of patients, and the decision to choose a treatment or 
another should be taken with responsibility, depending on currently existing medical records, the degree of expertise and not based 
on subjective or other non-standard parameters. 
 
Keywords: renal cancer, computed tomography, radical nephrectomy, 
nephron sparing surgery, active surveillance. 
Introduction 
The management of renal parenchymal tumors 
has known many changes over time, a trend that 
continues today as a result of technological advances, 
clinical research and improved diagnostic and therapeutic 
tools. 
Unfortunately, conventional cancer treatments - 
chemotherapy and radiotherapy have proven ineffective 
and modern approaches such as immunotherapy, 
angiogenesis inhibitors, though they enjoyed an initial 
enthusiasm, subsequent studies have shown limited and 
controversial effects. Thus, surgery remains the gold 
standard therapy for this type of cancer. 
Aggressive surgical approach to remove the 
whole tumor burden, here meaning both primary lesion 
and its extension - venous, lymphatic or metastatic - 
remains the only effective method that can ensure the 
cure, or, in some cases, the treatment of severe 
symptoms in order to increase the quality of life of these 
patients. 
During the first half of the twentieth century, 
simple nephrectomy was the standard treatment of renal 
parenchymal tumors. The first radical nephrectomy with 
removal of the kidney, adrenal gland and fat tissue within 
the Gerota’s fascia was reported by Mortensen in 1948 
[1]. In 1960, Robson and colleagues added the 
retroperitoneal lymph node dissection to the radical 
nephrectomy, reporting high rates of survival at 5 years 
[2,3]. 
Although the incidence of kidney cancer has 
increased significantly worldwide in recent years, most 
tumors are detected in early stages, when the 
conservative treatment can be performed with curative 
aim. Extensive use of abdominal ultrasound plus 
evaluation of the detected lesions by computer 
tomography, represent the diagnostic imaging tools that 
had the greatest impact in the immediate change of the 
clinical evolution of renal tumors. Thus, the concept of 
incidentaloma arose, because kidney cancer is often 
detected incidentally in countries with a developed 
medical system. 
In 1884, Wells performed the first partial 
nephrectomy for a kidney fibrolipoma and in 1887 Czerny 
did this type of intervention in a patient with solitary kidney 
(imperative indication). In 1950, Vermooten performed the Journal of Medicine and Life Vol. 4, No. 2, April‐June 2011 
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first partial nephrectomy in a patient with normal 
controlateral kidney (elective indication). Subsequently, 
surgical technique has evolved, but it still remains a 
challenge, especially for central tumors or in patients with 
imperative indications. Although these operations have 
been globally popularized and recommendations have 
been established and published in medical practice 
guidelines, a study published in the U.S. paradoxically 
showed, that an extremely low number of partial 
nephrectomy are made even for small renal masses [4]. 
Percutaneus ablative techniques (cryotherapy 
and radiofrequency ablation) have been improved in the 
last decade, with deeper knowledge of cellular 
metabolism and implications of low temperatures, i.e. 
ultrasounds on tumor cells. However, long-term results 
are contradictory, with still unacceptable risks related to 
recurrence and metastatic progression of the disease. 
Active surveillance, a relatively new concept in 
renal cancer, has an absolute indication in the presence 
of major comorbidities that prohibit surgical or 
percutaneous ablative techniques for patients with 
reduced life expectancy, with low performance status or 
patients who refuse surgery (relative indication). 
Although the depth of tumor progression 
mechanisms has evolved and the urologist’s 
armamentarium has been diversified, the question "why 
and how to treat all the kidney tumors?" still stands. 
  Small renal tumors, defined as T1a in the 
international TNM staging, have a risk of death of 5% at 5 
years without treatment and in T2 stage associates a risk 
of death of 27% over the same period of follow-up. On the 
other hand, approximately 30% of renal tumors, less than 
2 cm are benign, so they are not life-threatening [5]. In a 
study published in the Journal of Urology in 2006 Remzi 
reported that 11% of the tumors less than 3 cm are 
actually pathological pT3a, 5% are G3 as 
histopathological grading and 2.5% are metastatic at 
diagnosis [6], in other words trying to differentiate the 
aggressive from, the mild forms still remain a challenge 
for the urologist today. 
All these data confirm the lethal potential of small 
renal tumors, the possibility of local and systemic 
progression, with no mathematical correlation to the size. 
 
What are small renal masses (SRM) and how do we 
diagnose them properly? 
Imaging can provide objective answers to the 
clinician’s questions such as whether it is a tumor or not 
and its degree of development, relationship with adjacent 
structures, presence or absence of metastatic sites. A 
special feature is the anatomical position of this type of 
tumors, most accurately described by the investigation 
that can access the retroperitoneum, such as computer 
tomography or magnetic resonance imaging. 
Due to its accessibility and safety, renal 
ultrasonography became the first imaging method, 
essential in evaluating a patient with abdominal symptoms 
and the examination of a seemingly healthy individual 
who presents for a routine checkup or in postoperative 
protocols. The dependence on the expertise of physicians 
is the main disadvantage of ultrasound, plus the absence 
of direct information on renal function and excretory 
routes except for indirect signs such as uretero-and / or 
hydronephrosis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Intraoperative ultrasonography for detecting 
multicentric tumors or the parenchymal extension may be 
indicated in conservative renal surgery, but is not routinely 
applied. 
Renal ultrasound is not considered an ideal 
imaging method for screening because the lesions 
smaller than 2 cm may remain undiagnosed, but it can be 
used on selected groups of risk patients and 
asymptomatic elderly population [7]. 
Doppler ultrasound can accurately certify the 
presence of tumor thrombus in the inferior vena cava and 
the cranial extension, including right heart cavities, in 
which the transoesophageal echocardiography is 
mandatory. 
In fact, any renal mass with solid characters in 
the ultrasound exam has indication for contrast enhanced 
computer tomography examination, which is currently the 
election method for the detection, characterization and 
staging of renal masses. Spiral computer tomography with 
5 mm sections allows the identification and correct 
description of renal lesions with a minimum size of 1.5 
cm. We can use relatively thin slices of 2.5 mm in the 
kidney. 
Not all kidney tumors are well defined during the 
corticomedular phase, so the images obtained during late 
phase (nephrographic or excretory phase) should be 
included to facilitate the detection of renal masses, 
particularly small ones [8,9]. 
In addition, acquisitions in excretory phase 
(normally obtained after a scan delay of 3 minutes) are 
Fig. 1. Renal ultrasonography that detects a solid central 
mass in the left kidney (“Fundeni” Archives) Journal of Medicine and Life Vol. 4, No. 2, April‐June 2011 
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helpful to describe the anatomical abnormalities or renal 
collecting system invasion [10]. 
We consider that any difference higher than 20 
HU between SRM and the surrounding parenchyma with 
the presence of calcifications within a solid renal mass are 
imaging markers that suggest malignancy [11]. 
 
 
 
 
 
 
 
Magnetic resonance imaging (MRI) is used 
complementary to CT imaging only in cases where we 
cannot perform computed tomography (chronic renal 
failure, contrast allergy, etc.). 
 
Imaging SRM: is pathology correlated? 
Oncocitomas could be confused with clear cell 
renal tumors in terms of imaging features and degree of 
contrast load [12]. 
In contrast, Cromophobe carcinomas, are much 
more varied in terms of levels and patterns of contrast 
load. 
 
 
 
 
 
 
 
 
 
 
 
 
Negative densities are considered the mark of 
angyomiolipomas. High, homogeneous attenuation on 
native scan and charge on contrast have been reported in 
cases of angyomiolipomas, which contain more muscles 
fibers and less fat, or in cases of sarcomatous 
degeneration [13]. 
 
We have the diagnosis, how do we treat? 
The goal of treatment is to cure patients of 
cancer, preferably saving the kidney function and, if 
possible, with minimal perioperative morbidity. 
The choice of treatment depends on many 
factors, which are listed below: 
1. Tumor factors – stage, tumor size, location, 
Fuhrman's grading, histology, presence of tumor markers 
and receptors; 
2. Factors related to the patient: performance 
status (ECOG or Karnofski), age, renal function (global 
and controlateral kidney), cardiac function, comorbidities, 
surgical history, etc; 
3. Local facilities: open approach, laparoscopic, 
robotic and opportunities for cryoablation or 
radiofrequency, anesthetic and ICU support; 
4. Active participation of the patient to treatment 
(regular follow-up, appropriate compliance). 
Regardless of the treatment method we choose, 
the patient should be informed about the risks associated 
with each method: hemorrhagic risk, risk of positive 
margins, urinary fistula, the occurrence of postoperative 
acute kidney injury, intraoperative conversion from a 
laparoscopic/robotic approach to open and the need of 
conversion from partial to total nephrectomy. 
 
Treatment of SRM 
The options for the treatment of RCC are 
numerous, with options that have advantages and 
disadvantages, with oncological results, in most cases, 
Fig. 2. Mediorenal tumoral mass classified as T1, 
suggestive for RCC (“Fundeni” Archives) 
 
Fig. 3. a) Right renal oncocitoma (with central scar) – 
nephrographic phase; b) Bilateral renal angyomiolipomas 
(“Fundeni” Archives). Journal of Medicine and Life Vol. 4, No. 2, April‐June 2011 
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positive at five years and with different impact on cancer 
specific survival. 
Comparing the results is difficult, as these are 
different techniques and with various instruments and 
intraoperative steps, with more questionable inclusion 
criteria, selection biases and prosecution, with a tendency 
for preferential enrollment, different reasons to why 
randomized prospective studies have not been performed 
until today. 
 
We have three clear answers so far: 
1. Conservative surgery (NSS) has won the 
"battle" with radical nephrectomy in the treatment of small 
renal tumors. 
Why? 
a) If we perform NSS in a patient with normal 
controlateral kidney, we assume the probability of 20% at 
three years to develop chronic kidney disease (glomerular 
filtration rate <60 ml / min) and 65% probability for radical 
nephrectomy. We also have the misfortune of 5% after 
NSS at 3 years of having a severely reduced glomerular 
filtration rate (below 45 ml/min) and 36% after a total 
nephrectomy. In a study published by Thompson et al. in 
the Journal of Urology in 2008, patients with ages less 
than 65 years old, who had radical nephrectomy for SRM, 
had a lower overall survival rate than patients who 
underwent NSS. Thus, mortality from cancer in certain 
situations differs from that determined by other 
comorbidities [15]. 
b) At a glomerular filtration rate between 60-45 
ml / min, the relative risk of death from cancer is 1.2, the 
relative risk for cardiovascular events is 1.4 and for 
hospitalization is 1.1[16]. At a filtration rate between 45-
30ml/min, the relative risk of death from cancer is 1.8, the 
relative risk of cardiovascular events is 2.0 and for 
hospitalization is 1.5 and at a filtration rate between 15-30 
ml/min, the relative risk of death from cancer is 3.2, the 
relative risk of cardiovascular events is 2.8 and for 
hospitalization is 1.5. 
c) Overall survival at 5 and 10 years is 85.5% for 
radical nephrectomy and 88.9% for NSS and 10 years 
68.8% and 70.9%, respectively [16]. 
Conclusions: The oncological results are similar 
for both treatment modalities for small renal tumors - 
classified T1a, but NSS reduces the risk of nontumoral 
death and maintains the renal function (80% for NSS vs. 
35% for radical nephrectomy). 
2. The role of adrenalectomy 
Adrenalectomy is not routinely indicated except 
for the upper pole tumors or on suspicious adrenal lesions 
on CT or intraoperative. 
3.  According to EORTC, Locoregional lymph 
node dissection in renal cell cancer does not increase 
survival rate at 10 years [17]. 
The report concluded that a correct lymph node 
dissection does not bring a higher morbidity risk for the 
patient and the risk of lymph node-positive in patients who 
did not have imaging or intraoperative suspicion is 3.3%, 
which, according to the authors of the study does not 
justify the procedure. In our experience, which includes 
approximately 3800 renal tumors in various stages, 
operated in the past 10 years, this is an inappropriate 
management. Routinely performing locoregional lymph 
node dissection induces additional expertise, which does 
not associate a higher morbidity, it is not time consuming 
and the oncological results, at least for the microscopic 
invasion, are excellent. This concept of radical surgery 
finds its counterpart absolutely in open surgery. 
 
Radical surgery for SRM  
 
1. Open radical nephrectomy  
It has represented the gold standard procedure 
in the treatment of renal cell cancer over the years. 
However, in the last decade, due to good results reported 
by the NSS, its indication has become secondary. Global 
statistics for radical nephrectomy are presented as 
following [18]: mean hospital stay 6 days, 5% risk of 
readmission, mean intraoperative blood loss 325 ml, 16% 
risk of transfusion, 17% perioperative morbidity, mortality 
0.3%. In addition, the risk of reintervention after a radical 
nephrectomy is of 0.6% and local recurrence rate 
reported is 0.3%. Regarding the oncological outcome, 
cancer specific survival at 5 years reaches rates of 94-
98%. Radical nephrectomy is associated with a shorter 
hospitalization time, few type II and III complications on 
the Clavien scale, but it considerably increases the 
mortality from noncancerous specific events.  
2. Laparoscopic radical nephrectomy faithfully 
reproduces the steps of open surgery and has established 
itself as the standard treatment for tumors up to 14 cm in 
diameter. The oncological results, functional and 
complications are comparable to those of open surgery, 
although there is no solid evidence to confirm this. 
Operative time is similar to that recorded for open 
nephrectomy, but has the advantage of a faster recovery. 
No recurrences were reported at the trocars sites and 
cancer specific survival rate at 5 years is of 94-97% [19]. 
 
NSS is the new gold standard for small renal tumors 
(SRM) 
Regardless of the approach path and the 
available technology (open, laparoscopic, robotic), short-
term oncological results are similar, but, unfortunately, the 
long term are contradictory or even unpublished. The 
need for long-term studies in a prospective randomized 
fashion is imperative in order to impose new standards for 
the treatment of RCC. 
1. Open NSS has imperative, elective indications 
(normal controlateral kidney, accessible tumors under 4 
cm) and relative indications (kidney disease associated 
tumors larger than 4 cm, etc.). Early complications 
reported, mostly due to a warm ischemia time (WIT) 
higher than 20 minutes, have a rate of 13.4% and the late Journal of Medicine and Life Vol. 4, No. 2, April‐June 2011 
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complications are maintained at a high rate of 32%. 
Oncological results are translated into the local 
recurrence risk of 1.4% and 0.69% rate of systemic 
recurrence. Cancer specific survival for small renal tumors 
less than 4 cm is of 98% [20].  
 
 
 
 
 
 
 
2. Laparoscopic NSS is a still technically 
inaccessible procedure, which requires special expertise. 
All the studies show a 12-32% rate of complications, 
increased bleeding risk associated even with small 
tumors, mean operative time of 3 hours, warm ischemia 
time in experienced hands of over 25 min [21, 22, 23, 24] 
According to Gill's study, recently published with 
a remarkable honesty, the functional and oncological 
results obtained after 800 conservative operations 
laparoscopically performed, are improving, warm 
ischemia time (WIT) is reduced with increased risk of 
bleeding in early pedicle declamping, but, unfortunately, 
do not reach the results reported by open surgery. In 
addition, the learning curve even after this huge number 
of procedures is still on the ascendant trend [23]. 
In conclusion, laparoscopic NSS can be 
performed in centers of excellence, still technically 
difficult, and it is associated with a higher risk of 
complications. The need for new tools is imperative and 
well-managed long-term studies are required in order to 
establish this procedure as an indication in daily practice. 
Comparisons between laparoscopic and open 
NSS are unbalanced; studies evaluating patients in open 
surgery are more difficult in terms of extension and tumor 
size, comorbidities, etc. Additionally, the risk of positive 
margin, intraoperative complications, urologic and non-
urological surgery is higher after laparoscopy.  
Data published in the literature report similar 
oncological results of both procedures: cancer specific 
survival rates are of 99% and of 99.2% for laparoscopy 
and open surgery, respectively [25]. 
 
3. Robotic NSS 
 Although promoted in recent years, conservative 
robotic surgery is still in evaluation, with scarce medium 
and long-term results. Certain procedures, such as 
hemostasis and intracorporeal sutures are easier to 
perform than laparoscopy, with lower WIT. Oncological 
results are contradictory and time tracking of patients is 
still insufficient to bring this technique into standard 
surgical practice. 
 
3. Percutaneous ablative techniques in the 
treatment of small renal tumors (SRM), cryotherapy 
and radiofrequency ablation by HIFU. 
The mechanism of action involves the use of 
agents, which determine the precipitatation of intracellular 
proteins, thereby causing cell apoptosis and necrosis. 
Ablation uses currents generated by radiofrequency 
(RFA) and is indicated in tumors with certain specific 
locations. It obtains diffuse necrosis, with secondary injury 
to the surrounding tissue. On the contrary, cryoablation 
limits its action as it is focused only on tumor tissue.  
The need to introduce these procedures in the 
urological arsenal derives from the daily practice, as an 
alternative treatment for a difficult group of patients. Thus, 
those with low performance status, who present multiple 
comorbidities or those who refuse other more invasive 
procedures, have proved to be candidates for ablative 
techniques. In addition, tumors with a low malignant 
potential or those who have genetic syndromes such as 
Von Hippel-Lindau, can be candidates for one of these 
procedures. 
HIFU can be performed through a percutaneous 
or laparoscopic approach, but the paucity of studies 
available in the literature, along with poor functional and 
oncological results, maintain this technique as an 
experimental procedure in the treatment of RCC [26]. 
Cryotherapy can be performed laparoscopically 
(60% of the cases), percutaneously (30%) or by an open 
approach. Regardless of the approach path, general 
anesthesia and longer operative time are required, 
together with longer hospitalization. Between 
percutaneous and laparoscopic approach, looking in 
particular at the differences regarding the costs, the 
percutaneous approach is cheaper, and the transfusion 
risk is higher for laparoscopic approach (11% vs. 28%) 
[27]. 
The temperature at which cell death occurs 
depends on the type of the cell. Thus, in the kidney it is of 
-19.4 C. In kidney cancer it is situated at a temperature 
below -10C, 96% of the cells survive, reducing the 
percentage to 15% at -20 degrees C [28]. 
In addition to lowering the temperature, the time 
also matters, and a longer period seems to provide a 
better oncological status. The size of necrosis area 
assessed at 2 weeks, shows similar values, regardless of 
the needles’ size used in cryoablation [29]. 
Fig. 4. Open NSS – intraoperative aspect (“Fundeni” 
Archives)  
 Journal of Medicine and Life Vol. 4, No. 2, April‐June 2011 
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  Percutaneous radiofrequency ablation is 
performed in 90% of cases, so it requires sedation in most 
cases, which brings lower operative time and overall, 
lower costs. 
 
Do these procedures imply no complications? 
The answer is definitely not, some of them are 
severe and we question ourselves whether these are 
minimally invasive techniques. The following are reported 
in literature: kidney, liver or pancreas laceration, kidney 
hematoma, intestinal obstruction, pieloureteral junction 
syndrome, urinary fistula, conversion to open surgery, etc. 
Overall, the rate of major perioperative morbidity for both 
procedures is, regardless of the approach, between 0.8 
and 4% (higher for percutaneous RFA). [30] 
The Cryotherapy and radiofrequency ablation 
preserves pre-existing renal function. However, the 
studies analyzed, showed that 20% of the patients with 
chronic kidney failure who have a glomerular filtration rate 
below 60 ml / min, of which 15.5% had de novo CKD [31]. 
Long-term oncological results are scarce and 
contradictory; only one study has a follow-up period of 5 
years on cryotherapy, the overall survival rate of 84% 
being reported, the cancer specific survival rate of 92% 
and 81% specific-disease free [32]. 
There are also two studies that reported data on 
cancer outcomes for patients treated with RFA, with a low 
number of individuals enrolled, with cancer specific 
survival rate of 94-100% and the risk of local and 
systemic recurrence of 5-10%, which is unacceptable 
from our point of view. The risk of local progression 
reported for cryotherapy is of 5.2% compared to 13% for 
radiofrequency ablation and the systemic progression of 
1% and 2.5%. Regarding the risk of reablation, Lavinson 
et al. reported a rate between 1.3% to 8.5% for 
cryotherapy and RFA, respectively [33, 34]. 
Energy ablative techniques remain an alternative 
to radical/conservative surgery, but the results and criteria 
for evaluation of treatment response are still being under 
evaluation. The follow-up is done purely radiologically 
and, in many cases, they were positive after rebiopsy, 
with no corresponding imaging for active tumor. After 
such procedures, salvage surgery is "challenging", 
whether we consider conservative or radical surgery. 
Active surveillance, a relatively new concept in 
renal oncology, has an absolute indication in the presence 
of major comorbidities that prohibit any type of surgical 
approach or energy ablative techniques in patients with 
reduced life expectancy, with low performance status or 
patients who refuse surgery (relative indication). 
The theory behind this procedure derives from 
the observation that 30% of the SRM do not grow in size, 
and from those that are still progressing, most of them 
slowly grow about 0.3 cm / year, few reaching rates 
higher than 1 cm/year. Also, there is no correlation 
between growth rate and prognosis of patients; in addition 
any degree of aggressiveness of the tumor cannot be 
forecasted based on this parameter [35]. 
However, there is no long-term data in order to 
establish the place of this method in the renal cancer 
therapeutic arsenal, but has a follow-up period higher 
than that of percutaneous ablative techniques, or even for 
laparoscopic NSS, and many clinicians consider active 
surveillance beneficial when compared to other 
procedures mentioned, at least from this point of view. 
 
What do we know so far about the active surveillance 
of SRM? 
In a study published in 2006 by Chawla, the 
authors report a systemic progression rate of 1% in the 
group studied [35]. A year later, Abou Youssif published 
an article, which reported that 5.7% of patients developed 
lung metastases during follow-up period [36], and Crispen 
reported in 2009 a 1.3% rate of systemic progression [37]. 
In conclusion, patients under active surveillance 
have an average risk of systemic progression of 1-2% and 
as a general observation, we can say that progressing 
tumors tend to grow faster. However, deaths during the 
studies were not caused by cancer, in other words, 
cancer specific survival was of 100%. 
Unfortunately, several questions remain 
unanswered; one of the unknowns is when to decide to 
stop actively monitoring the patients and shifting them to 
surgical treatment. Thus, losing the window of opportunity 
for a radical curative therapy remains a constant concern. 
In addition, tumor aggressiveness, regardless of size, 
cannot be predicted earlier, and opponents of this method 
consider it hazardous to monitor this type of tumor taking 
into account its high risk of progression. Also, the 
proportion of benign lesions, which theoretically would be 
amenable for such therapy, is not known precisely.  
When do we stop active surveillance? 
According to present recommendations for 
complex cases included in genetic syndromes (von 
Hippel-Lindau syndrome, etc.), active surveillance ceases 
when the tumor reaches 3 cm in diameter. Secondary 
renal tumors, with proven tumor progression in two 
successive evaluations, require at least caution, if not 
stopping of the active surveillance [37]. More subjective 
factors relating to the patients, their refusal to continue the 
monitoring and the decision to operate, must be taken into 
account in order to stop the surveillance and proceed to 
another therapeutic approach. 
 
Renal biopsy has emerged as an effective 
diagnostic method and has lately improved due to the 
perfection of the technique itself, but also due to 
popularized conservative therapies. It can be performed 
under ultrasound guidance or under tomography, the first 
approach with a longer learning curve and can be 
technically difficult, especially in obese patients. 
Depending on the manner of execution, such as 
needle type and the material collected, renal biopsies may Journal of Medicine and Life Vol. 4, No. 2, April‐June 2011 
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be aspirative (FNA) or type core, both with high sensitivity 
(90%), except that the aspiration method has a lower 
sensitivity for Fuhrman grade and requires the 
interpretation from an experienced cytologist. 
No major complications (transfusion, 
embolization, and surgical reinterventions) were reported, 
there are some are cited most frequently. According to an 
article published in 2009 by Lechevallier, kidney 
subcapsular hematoma is met in an alarming proportion 
of 44%, followed by arteriovenous fistula, pneumothorax, 
bowel perforation [38]. The risk of tumor seeding, uro-
oncologists once feared has disappeared, being 
described in only six cases, the last one being reported in 
1992. 
 
Is renal biopsy useful? 
The method has a sensitivity of 70-100%, 
specificity of 100%, accuracy of 90%, performance 
parameters that have promoted this method in clinical 
practice. However, we believe that these indices are 
overrated and the abuse of such procedures is 
detrimental to the patient and to the oncological 
management of the tumor. In addition, the nephrology and 
transplantation daily practice and we agree that, in a 
significant proportion of cases, the pathologist 
interpretations are ambiguous. In large studies, this 
percentage increases to 25% of patients and therefore 
biopsy is nondiagnostic and induces major confusions 
with a delay of treatment with curative visa [39]. 
We believe that renal biopsy is useful whenever 
afterwards, the therapeutic attitude changes or in selected 
cases of secondary kidney tumors, if we suspect a 
metastasis from another cancer or lymphoma, before 
energy ablation therapy or prior to treatment with 
angiogenesis inhibitors. However, if the tumor is smaller 
and more centrally located, the more chances we have for 
a negative biopsy. In cases of large tumors, the 
harvesting of tissue from the necrotic or hemorrhagic 
areas poses a high risk for blending that needs to be 
taken into consideration. 
Tumor markers have been studied extensively in 
the pathogenesis of RCC. The results are disappointing, 
the need for such biochemical parameters for the 
diagnosis and monitoring of patients is imperative. The 
following markers have been reported: carbonic 
anhydrase, Ki67, C-reactive protein, although initially they 
seemed promising, they have passed on the second 
place, never being evaluated prospectively. 
Prognostic nomograms have been developed for 
the design development of kidney cancer patients. Most 
of them are based on tumor histology, but their clinical 
use is limited [40, 41, 42]. 
 
NSS vs. cryotherapy vs. RFA vs. AS in the treatment of SRM 
  No patients  Follow-up  Local progression 
(relative risk) 
Systemic progression 
(relative risk) 
NSS  5037  54 mths  1  1 
Cryotherapy  496  18 mths  7,45  1,24 
RFA  607  16,4 mths  18,23  3,21 
Active surveillance  331  33,3 mths  -  0,11 
 
Conclusions 
The risk of local recurrence is 7 and 18 times 
higher for cryotherapy and radiofrequency ablation versus 
conservative surgery or active surveillance; in addition, 
recurrences require radical surgery, which is difficult to 
perform after ablative techniques because of secondary 
fibrosis [43]. A high positive biopsy rate after RFA, which 
has no counterpart tumor imaging (MRI), has also been 
reported [44]. 
Partial nephrectomy, with all its technical forms 
(open/laparoscopic, enucleation/enucleoresection vs. 
wedge/partial nephrectomy) has become the new gold 
standard for the treatment of small renal tumors, although 
it remains underused. Approximately 27% of RCC T1 is 
treated by NSS in the U.S., the rest being solved by 
radical nephrectomy [45]. Partial nephrectomy brings a 
proven level of technical difficulty, especially for tumors on 
anterior valve, centered, large or upper renal pole, but 
overall perioperative morbidity related parameters remain 
within acceptable limits, which are improving with 
experience. However, in postoperative bleeding, the risk 
of urinary fistula are complications which the urologist 
must be familiar with, as coagulation and suturing 
techniques have improved, a significant percentage of 
patients, especially those with imperative indications, 
unfortunately have the risk to present such unwanted 
postoperative events. 
Ablative techniques have not yet shown efficacy 
in patients without major contraindications for surgery and 
patients who choose such treatments must be informed of 
all treatment alternatives. Selecting an ablative technique 
is risky, both in short and long term, when it comes to 
cancer free survival rates. Pressure applied by patients 
who want the therapy with the lowest physical and 
psychological impact and by innovative companies should 
not be exercised in order to radically alter the therapeutic 
decision. The urologist must decide which approach is 
more familiar to him and which one has proven the best 
results for the patients, not letting the medical industry 
determine the method instead. A quick solution, with 
minimal impact on the health care system and patient’s 
quality of life, does not always cure the patient or at least 
provide a good oncological prognosis. 
At the beginning of the new millennium, kidney 
cancer with all the arsenal of techniques and methods of Journal of Medicine and Life Vol. 4, No. 2, April‐June 2011 
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ablative surgery, remains a potentially fatal disease for a 
high percentage of patients, and, the decision to choose a 
treatment or another should be taken with responsibility, 
depending on currently existing medical records, the 
degree of expertise and not by subjective or other non-
standard parameters. 
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